Insmed (INSM) Tops Q3 EPS by 2c ; Offers Guidance
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $126.29 -0.31%
Revenue Growth %: +253.1%
Financial Fact:
Operating loss: -37.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +253.1%
Financial Fact:
Operating loss: -37.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q3 EPS of ($1.11), $0.02 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $79.1 million versus the consensus estimate of $79.14 million.
GUIDANCE:
Insmed sees FY2023 revenue of $295-305 million, versus the consensus of $303.4 million.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
